{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:46:01Z","timestamp":1784940361920,"version":"3.55.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Although there is early support for schemes based on nuclear grade, necrosis and mitotic rate, there is currently no widely implemented grading system for diffuse pleural mesothelioma (DPM). We investigated current systems and propose a novel Mesothelioma Weighted Grading Scheme (MWGS). The MWGS assigns weighted scores from 0 to 10 based on age (\u226474, &gt;74 yrs: 0,1); histologic type (epithelioid, biphasic, sarcomatoid: 0,1,2); necrosis (absent, present: 0,2); mitotic count per 2\u2009mm<jats:sup>2<\/jats:sup> (\u22641, 2 to 4, \u22655: 0,1,2); nuclear atypia (mild, moderate, severe: 0,1,2); and <jats:italic toggle=\"yes\">BRCA1-associated protein 1<\/jats:italic> (BAP1) expression (lost, retained: 0,1). A score of 0 to 3 is low grade, 4 to 6 intermediate grade, and 7 to 10 high grade. In 369 consecutive DPMs, median survival was 17.1, 10.1, and 4.1 months for low, intermediate, and high grades (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001). A progressive increase in score correlated with worsening overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001). Interobserver concordance was substantial (\u03ba=0.588), with assessment of nuclear grade being the most subjective parameter (\u03ba=0.195). We compared the MWGS to the 2-tiered system discussed in the World Health Organization (WHO) fifth edition. The WHO system predicted median survival in epithelioid (median 18.0 vs. 11.3\u2009mo, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.003) and biphasic (16.2 vs. 4.2\u2009mo, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.002), but not sarcomatoid DPM (5.4 vs. 4.7\u2009mo, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.407). Interestingly, the WHO grading system was prognostic in cases with BAP1 loss (median survival 18.7 vs. 10.4\u2009mo, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001), but not retained BAP1 expression (8.9 vs. 6.2\u2009mo, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.061). In conclusion, the WHO scheme has merit in epithelioid\/biphasic and BAP1-deficient DPM, however, the MWGS can be used for risk stratification of all DPMs, regardless of histologic subtype and BAP1 status.<\/jats:p>","DOI":"10.1097\/pas.0000000000001854","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T13:23:46Z","timestamp":1639574626000},"page":"774-785","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS)"],"prefix":"10.1097","volume":"46","author":[{"given":"Talia L.","family":"Fuchs","sequence":"first","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Chou","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagiz","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahiar","family":"Mahjoub","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sheen","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Sioson","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Ahadi","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1177\/09603271211017324","article-title":"The usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma","volume":"40","author":"Tanriverdi","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/oem.2007.037002","article-title":"The burden of cancer at work: estimation as the first step to prevention","volume":"65","author":"Rushton","year":"2008","journal-title":"Occup Environ Med"},{"key":"R3-20250608","first-page":"162","article-title":"Latency periods in asbestos-related mesothelioma of the pleura","volume":"6","author":"Bianchi","year":"1997","journal-title":"Eur J Cancer Prev"},{"key":"R4-20250608","first-page":"1","article-title":"Malignant pleural mesothelioma epidemiology in the United States from 2000 to 2016","volume":"13","author":"Thomas","year":"2021","journal-title":"Cureus"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2007.04.076","article-title":"Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"84","author":"Rice","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtcvs.2014.10.041","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience","volume":"149","author":"Lang-Lazdunski","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J Clin Oncol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2017.08.012","article-title":"National Cancer Database Report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma","volume":"12","author":"Verma","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J Surg Res"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the national lung cancer audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Canc"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 world health organization classification of tumors of the pleura: advances since the 2004 Classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1183\/09031936.00207213","article-title":"Multimodal management of malignant pleural mesothelioma: where are we today?","volume":"44","author":"Van Schil","year":"2014","journal-title":"Eur Respir J"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLOS One"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/gcc.22381","article-title":"Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis","volume":"55","author":"Luchini","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","article-title":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","volume":"60","author":"McGregor","year":"2017","journal-title":"Hum Pathol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.13392","article-title":"The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma","volume":"72","author":"Chou","year":"2018","journal-title":"Histopathology"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal","volume":"13","author":"Pelosi","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","article-title":"Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies","volume":"470","author":"Habougit","year":"2017","journal-title":"Virchows Arch"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting. An external validation study of 563 cases","volume":"33","author":"Zhang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center","volume":"13","author":"Galateau-Salle","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/PAS.0000000000001505","article-title":"A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (Ki67 and mitotic count) and coagulative necrosis","volume":"44","author":"Fuchs","year":"2020","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:06:34Z","timestamp":1749416794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001854","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,15]]}}}